Dr. Sazaly has been involved with dengue research for over 20 years and has also maintained strong research interest in emerging infectious diseases. His interest in dengue, in particular, is rooted in its knowledge gaps: “it is a fascinating disease needing a lot more research to take on.” In an interview with DVI, Dr. Sazaly shares more on his views of dengue prevention and control and needs in the dengue research field.

Dengue Vaccine Initiative Statement on Results of Studies on the Efficacy and Long-Term Safety of Sanofi Pasteur’s Dengue Vaccine Candidate in Dengue-Endemic Regions

WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.

Every three months, the Dengue Vaccine Initiative (DVI) highlights a “Dengue Champion,” calling attention to that person’s contribution to the dengue vaccine research field and their commitment to the fight against dengue fever. Dr.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

Pages